Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: A clinical-stage biopharmaceutical company developing small-molecule therapeutics for age-related degenerative diseases of the central nervous system (CNS) and retina. The lead product candidate is zervimesine (CT1812), targeting Alzheimer's disease, dementia with Lewy bodies (DLB), and geographic atrophy (GA). The company operates as a single segment focused on R&D.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue (Grant Income) | $12,192 | $12,223 |
| Total Operating Expenses | $27,753 | $28,780 |
| Net Loss | $(15,214) | $(16,192) |
| Net Loss Per Share (Basic & Diluted) | $(0.24) | $(0.44) |
| Cash and Cash Equivalents (End of Period) | $10,743 | $28,533 |
| Restricted Cash Equivalents | $814 | $0 |
| Total Liquidity (Cash + Restricted) | $11,557 | $28,533 |
| Accumulated Deficit | $(190,374) | $(157,381) |
| Net Cash Used in Operating Activities | $(15,500) | $(13,241) |
Material Changes vs. Prior Period
- Net Loss Improvement: Net loss decreased by $0.98 million (6%) to $15.2 million for the six months ended June 30, 2025, compared to $16.2 million in the prior year period. This was driven by a $1.0 million reduction in operating expenses.
- Operating Expenses: Total operating expenses declined by $1.0 million. General and Administrative (G&A) expenses decreased by $1.2 million, primarily due to lower equity-based compensation. Research and Development (R&D) expenses increased slightly by $0.1 million due to increased clinical trial activities, offset by reductions in manufacturing and preclinical costs.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $14.3 million from the beginning of the period, reflecting a net cash burn of $15.5 million from operations, partially offset by $2.0 million in financing proceeds from At-The-Market (ATM) sales.
- Grant Receivables: Grant receivables increased significantly to $6.3 million from $2.7 million at year-end 2024, indicating a timing difference between incurring reimbursable costs and receiving payments from the National Institute of Aging (NIA).
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months. As of August 7, 2025, cash on hand is deemed insufficient to fund operations for one year without additional financing.
- Clinical Progress:
- Alzheimer's (SHINE Study): Met primary endpoints for safety. Subgroup analysis showed a 95% reduction in cognitive decline for patients with low baseline plasma p-tau217. An end-of-Phase 2 meeting with the FDA was held in July 2025.
- Dementia with Lewy Bodies (SHIMMER Study): Met primary endpoints. Treated patients showed significant improvements in behavioral, functional, cognitive, and motor scales. An expanded access program (EAP) was funded by a philanthropic donation in June 2025.
- Geographic Atrophy (MAGNIFY Study): Voluntarily concluded in January 2025 to focus resources on CNS indications. Results showed slower lesion growth compared to placebo.
- Capital Resources: The company raised approximately $2.4 million via ATM sales in the first half of 2025. Approximately $19.5 million remains available under the ATM facility, and $34.8 million remains available under the Lincoln Park equity line financing.
- Nasdaq Listing Risk: The company received a deficiency letter regarding the minimum $1.00 bid price requirement. It transferred to the Nasdaq Capital Market in March 2025 and has an additional 180-day grace period (ending September 8, 2025) to regain compliance. Failure to comply could result in delisting.
- Regulatory Risks: Potential disruptions to FDA operations due to government funding issues or policy changes under the new 2025 administration could delay regulatory reviews.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($11.6M) plus obligated NIA funds ($41.9M) against projected burn rates to confirm the timeline for needing new capital.
- Nasdaq Compliance: Monitor the stock price to ensure it meets the $1.00 minimum bid price requirement before the September 8, 2025 deadline to avoid delisting.
- Grant Funding Reliance: Assess the risk associated with the heavy reliance on NIA grants (approx. $171M cumulative) and the potential impact of government budget changes or audit findings on future reimbursements.
- Phase 3 Pathway: Review the formal minutes from the July 2025 end-of-Phase 2 meeting with the FDA to understand the specific requirements for the proposed Phase 3 program.
- Dilution Risk: Evaluate the potential dilution from future equity raises, given the company's need for substantial additional funding to sustain operations and advance clinical trials.